Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD - PR Newswire (press release)

Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD PR Newswire (press release) Topline results revealed the study met its primary endpoints for both doses of SHP465 (12.5mg and 37.5mg) administered once daily, indicating superiority over placebo in ADHD symptom improvement (p<0.001). Key secondary endpoint was also met for ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFoWKbdJXHqgPSPN9XVsaPrupbkug&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779143733902&ei=zp10V9iaM5DB3gHk97nQAw&url=http://www.prnewswire.com/news-releases/shire-announces-positive-topline-results-of-shp465-efficacy-and-safety-study-in-adults-with-adhd-584834201.html
via IFTTT